×
0 0 0 0 0 0.00860969387755112 0.00829081632653066 0.010841836734694
Stockreport

EC OKs Roche's MS med Ocrevus [Seeking Alpha]

ROCHE HOLDING LTD SPON (RHHBY)  More Company Research Source: Seeking Alpha
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF EC OKs Roche's MS med OcrevusThe European Commission (EC)approves Roche's (OTCQX:RHHBY) OCREVUS (ocrelizumab) for the treatment of patients with active relapsing forms of multiple sclerosis (MS) and patients with early primary progressive MS.Ocrelizumab, a humanized monoclonal antibody targeting CD20-positive B cells, is administered once every six months via intravenous infusion.OCREVUS was previously approved in the U.S., Canada and Australia.Click to subscribe to real-time analytics on RHHBYNow read:Roche Obtains FDA Approval For Hemophilia A Drug, Time To Push Shire Out » [Read more]

IMPACT SNAPSHOT EVENT TIME: RHHBY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
RHHBY alerts
from News Quantified
Opt-in for
RHHBY alerts

from News Quantified
Opt-in for
RHHBY alerts

from News Quantified